Pulmatrix, Inc. (PULM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.6300 |
| Open | 4.6800 |
| Bid | 4.6000 x 1200 |
| Ask | 4.9100 x 1400 |
| Day's Range | 4.6200 - 4.7700 |
| 52 Week Range | 4.0320 - 20.8000 |
| Volume | |
| Avg. Volume | 62,261 |
| Market Cap | 15.649M |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.1950 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PULM
Related Research
- Pulmatrix, Inc.Mid Cap U.S. Pick List August 2022This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.RatingFair ValueEconomic Moat9 days agoMorningstar
- PR Newswire
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2022 and provided a corporate update related to its development programs.
- PR Newswire
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the dosing of the first five subjects in a Phase 1 trial evaluating PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine (DHE). PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine.
- PR Newswire
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced first quarter financial results for 2022 and provided a corporate update.
